Oxford Vacmedix
Develop therapeutic agents for the treatment of cancer
About Oxford Vacmedix
Oxford Vacmedix, established in 2012 as a spinout from Oxford University, focuses on developing therapeutic agents for cancer treatment. The company's core innovation lies in the use of Recombinant Overlapping Peptides (ROP) to create new immunotherapy treatments. These agents activate the immune system to directly attack tumors, reducing the need for invasive treatments like chemotherapy and radiotherapy. This approach not only enhances the effectiveness of cancer treatment but also makes it more economical and easier to deliver.
Oxford Vacmedix primarily serves the healthcare and pharmaceutical sectors, targeting patients and medical professionals seeking advanced cancer treatment options. The company operates in the global biopharmaceutical market, which is characterized by high growth potential and significant demand for innovative cancer therapies.
The business model of Oxford Vacmedix involves extensive research and development (R&D) to create and refine its immunotherapy agents. The company generates revenue through grants, partnerships, and potential future sales of its therapeutic agents. Notably, the company has received funding from Innovate UK to support the clinical development of its lead cancer vaccine, OVM 200.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Oxford, United Kingdom
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 46.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Non-Invasive medical devices and treatments, Spinout, Biotech and Pharma, Hard Tech, DT and LS, uk is8 life sciences, UKSU, UKSU2010
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | May 2025 | $1.5M | $6M | Undisclosed | ↗ |
| GRANT✓Other financing | Dec 2024 | $976K | — | UK Research and Innovation | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Oxford Vacmedix is 1.5K monthly website visits, down 6.3% over the last three months. Oxford Vacmedix's team grew 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 SpireaAdvanced antibody-drug conjugate technology for cancer therapeutics |
Harrogate, United Kingdom | Operational | 8 | $3.8M | $13M |
 GelmetixInjectable polymer gel for non-surgical chronic pain treatment |
London, United Kingdom | Operational | |||
 DJS AntibodiesAntibody therapeutics for chronic inflammatory and fibrotic diseases |
Oxford, United Kingdom | Acquired | |||
 Argonaut TherapeuticsDeveloping epigenetic therapies targeting abnormal arginine methylation |
Oxford, United Kingdom | Acquired | |||
 FemtogenixDNA-interactive payloads for antibody-drug conjugates |
St Albans, United Kingdom | Operational | |||
 AutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases |
London, United Kingdom | Operational | |||
 IGEM TherapeuticsImmuno-oncology IgE antibodies for treating solid tumors |
London, United Kingdom | Operational | |||
 KinomicaPhosphoproteomic diagnostic platform for precision oncology therapy selection |
Macclesfield, United Kingdom | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Oxford University Innovation
UK Research and Innovation
Other known investors2 additional known investors
University of Oxford
OUI Startup Incubator
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Oxford Vacmedix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oxford Vacmedix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.